ASCO 2025 | Community oncology infrastructure for adoptive cell therapies
James Smithy, MD, MHS, Memorial Sloan Kettering Cancer Center, New York, NY, emphasizes the need for well-established day hospital settings in community practice to safely deliver intensive adoptive cell therapies for solid tumors, highlighting the importance of rapid transfusions, lab results, and interdisciplinary care. Dr Smithy notes that community practice requires careful consideration of managing patients safely and effectively after discharge. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
These are fairly intensive regimens both on the inpatient and outpatient side. So I think having a really well established day hospital setting where patients can get rapid transfusions, rapid labs, and have kind of interdisciplinary care between hematologists and solid tumor oncologists is really important. I feel at large academic centers, this is very much built in, but I think in community practice, thinking about how to manage these patients in a safe and effective way after discharge is really important...
These are fairly intensive regimens both on the inpatient and outpatient side. So I think having a really well established day hospital setting where patients can get rapid transfusions, rapid labs, and have kind of interdisciplinary care between hematologists and solid tumor oncologists is really important. I feel at large academic centers, this is very much built in, but I think in community practice, thinking about how to manage these patients in a safe and effective way after discharge is really important. Thank you.
Read more...
